Best Caleb Hodgson Podcasts (2024)

1
A revival in neuro therapeutics 40:29

4h ago40:29

40:29

The neuroscience sector has seen a surge in investment over the past year, leading to breakthroughs and high-stakes deals, especially in the closing months of 2023. This momentum shows no signs of slowing, as companies continue to push boundaries in neuroscience and psychiatric disease research. At this year's Fierce Biotech Summit on Oct. 1, pharm…

1
Season 1 Recap + Season 2 Predictions 2:30:22

1h ago2:30:22

2:30:22

Caleb and Hunter deep dive into everything that happened in Season 1 of House of the Dragon. They tackle the Council of 101 AC, the character changes mid-season, the relationship between Alicent and Rhaenrya, the main differences between the show and the book, set pieces, sound design, costume design, favorite moments of season 1, and predictions f…

1
Robert Saleh gets Fired, Officially Drake Maye Season, Raiders Stuck on the Roller Coaster, Whats Wrong with the 49ers? 1:27:01

1d ago1:27:01

1:27:01

The Fiends jump straight into the news of the day with a discussion about Robert Saleh getting fired by the Jets (0:16 - 14:38). Brett’s expectations as Drake Maye gets the start in week six against the Texans (14:39- 29:17). Up next for the boys is a deep dive into the 49er's struggles on both ends and what Hunter's expectations for the rest of th…

1
Breaking down BIOSECURE—Industry implications and what comes next 20:02

5d ago20:02

20:02

Since the introduction of the BIOSECURE Act in January, named companies and U.S.-based biopharmas alike have speculated on what the legislation could mean for the life sciences industry. In this week's episode of "The Top Line," Fierce Pharma staff writer Fraiser Kansteiner sits down with Arnold & Porter’s Life Sciences practice chair Dan Kracov to…

1
Davante Wants Out of Vegas? NFL Week 4, No Max No Problem? 49ers Dominate the Pats...Kinda? 1:16:03

9d ago1:16:03

1:16:03

Caleb hates “sources”, as the boys explore the Tuesday drama linked to the supposed Devante Adams trade request (0.00-11:50). Raiders take down Massage Watson, With Caleb and Brett breaking down the scrappy Raiders defense, along with the rising star Brock Bowers. (11:57-27:30). We have a Pod faceoff on our hands!!! Brett tells the hard truth about…

1
ESMO, WCLC lung cancer data spark hope—and debate 23:17

12d ago23:17

23:17

At the recent World Conference on Lung Cancer and European Society for Medical Oncology annual meetings, two packages of lung cancer data from a partnership between Akeso and Summit Therapeutics and another collaboration between iTeos Therapeutics and GSK showed much promise of disrupting the current standard of care. But they also drew some questi…

1
Week 3 NFL Recap, Life at 1-2, Officially Drake Maye watch, Raiders "Business decisions”, 49er Hangover? 1:02:56

16d ago1:02:56

1:02:56

Segments "Film Talk" with Brett Pats Jets (TNF ) Positives/Worries Maye garbage time reps? Outlook for the rest of the season @ 49ers next week Niners Rams (Injury Bowl) QB Show Positives/worries Outlook for 49ers rest of season Mcvay/Shanny Raiders Panthers Fluke or panic time in LV? APs comments Positives/worries Outlook for Raiders rest of seaso…

1
Week 2 NFL Recap, Week 3 College Football Recap 1:20:22

16d ago1:20:22

1:20:22

Show Script Raidas upset the Ravens Mad Max = Game Wrecker Who’s laughing at Bowers's pick now? Road to Success looking ahead? Gardner's stats look good lol Niners vs Vikings: The Flores Game Injuries haunting? Did Flores outcoach Shanny?- Fred Warner becoming an all-time great ILB What is it about Kyle's drop-back game that has experts questioning…

1
Recapping Digital Pharma East 2024 8:23

19d ago8:23

8:23

In this week's episode of "The Top Line," we’re recapping and discussing the major trends from Digitial Pharma East, which took place in Philadelphia last week. The event brought together marketing experts from across the life sciences industry. Fierce Pharma Marketing's Andrea Park and Ben Adams talk about major trends from the event that came up …

1
A closer look at the Fierce 50 7:24

26d ago7:24

7:24

In this week's episode of "The Top Line," we will dive into the annual Fierce 50 special report. We share the stories of a select few 2024 Fierce 50 honorees and interesting highlights from this year's special report. To learn more about the topics in this episode: Fierce 50 of 2024 Innovation Honorees Health Equity Honorees Social Impact Honorees …

1
Week 1 NFL Recap, Week 2 CFB Recap 58:01

1M ago58:01

58:01

Segments - MNF: 49ers dominate the Goddamn Jets - Manning cast with Bill - Pats upset the Bengals - Raiders lose to the Chargers - NFL Redzone recap - SJSU vs Air Force - Oregon vs Boise St - Colorado Clickbait - Bama vs USFBy Eclection Podcasts

1
A look at flu vaccine manufacturing and supply in the post-pandemic era 17:10

1M ago17:10

17:10

In this week's episode of "The Top Line," we’re looking at what goes into manufacturing and supply of flu vaccines. Fierce Pharma’s Zoey Becker chats with Stefan Merlo, vice president of commercial operations, North America at CSL Seqirus. He discusses the company's differentiated flu vaccine portfolio and how its manufacturing process has evolved …

1
Goodbye to the PAC 12, CFB Week 1 Recap, Week 1 NFL Preview 1:43:37

1M ago1:43:37

1:43:37

Caleb's Intro - Farewell to the Pac12 intro CFB Week 1 Recap: - Conference realignment - NIL World - Expanded 12-team playoff - Brian Kelly Hate session - Has Colorado improved? - Hunter and Sanders as NFL Prospects? SJSU vs Sac State - Coach Ken wins in debut - Is Nick Nash a "Biletnikoff" threat? NFL? - Predictions for a new era at SJ Oregon Chec…

1
Driving flu vaccine uptake in the post-pandemic era 20:46

1M ago20:46

20:46

In this week's episode of "The Top Line," we look at factors driving the continuing decline of flu vaccination rates in the U.S. and beyond. Fierce Pharma’s Zoey Becker chats with Gregg Sylvester, M.D., Chief Health Officer at CSL Seqirus, to get insight on what we might expect to see from this upcoming flu season. He also explains efforts to incre…

1
NFL Preview 1:39:36

1M ago1:39:36

1:39:36

Intro: Welcome Brett Orloff to the Fiends Explain the new show format NFL Football Preview/Half-Baked Predictions Raiders Preview with Caleb 49er Preview with Hunter Pats Preview with Brett Super Bowl predictions MVP predictions 1-2 half-baked takes per person…… (revisit after season)By The Fiends Podcast Network

1
The Crucial Role of HEK293 DNA Quantification in Biotherapeutics [Sponsored by Bio-Rad Laboratories] 13:42

2M ago13:42

13:42

Biotherapeutics are transforming healthcare for over 350 million patients globally, tackling everything from cancer and diabetes to rare diseases. Human embryonic kidney (HEK) 293 cells play a key role in the manufacturing of many of these life-changing products. However, they are not without their challenges. In this episode of The Top Line, spons…

1
What Chevron’s overturn means for biopharma 25:15

2M ago25:15

25:15

For the last 40 years, when federal legislation was ambiguous or left an administrative gap, courts were required to defer to the interpretation of agencies. This stipulation, called the Chevron deference, gave agencies room to advance their regulatory priorities. The Supreme Court overturned the doctrine in June, bringing significant implications …

1
The TROP2 race for supremacy 24:41

2M ago24:41

24:41

The TROP2 antibody-drug conjugate race has heated up among three Big Pharma companies: Gilead Sciences, AstraZeneca and Merck. Fierce Pharma’s Angus Liu recently took a deep dive into the three TROP2 front-runners. In a feature article, he examined the strengths and potential challenges facing each candidate, as well as the considerations behind th…

1
A closer look at Fierce Biotech's Fierce 15 11:17

2M ago11:17

11:17

In this week's episode of "The Top Line," we’re diving into Fierce Biotech’s annual Fierce 15 special report. Fierce Biotech's Annalee Armstrong and Gabrielle Masson take you behind the scenes to explore the meticulous selection process and share interesting highlights from this year’s honorees. To learn more about the topics in this episode: Intro…

1
What 'The Next Berlin Patient' and a PrEP’s 100% efficacy mean for HIV drug development 26:38

2M ago26:38

26:38

This week on “The Top Line,” we discuss two studies in HIV research that were presented at the 25th International AIDS Conference in Germany. One of them is the report of a 7th person who has likely been cured of HIV. And there’s something unique about this case that has sparked excitement among scientists. The other one is the report of a long-act…

1
Fierce 15: Where are they now? 10:02

3M ago10:02

10:02

In this week’s episode of "The Top Line," Fierce Biotech’s Annalee Armstrong highlights some of the most promising companies that made our prestigious Fierce 15 list back in 2014. A decade later, she revisits these trailblazers to see how they’ve navigated the biotech landscape. To learn more about the topics in this episode: Fierce Biotech's Fierc…

1
Former FTC director weighs in on Novo's $16.5B deal with Catalent 17:18

3M ago17:18

17:18

Back in February, Novo Holdings laid out a $16.5 billion deal to snap up contract manufacturing giant Catalent. In this week's episode of "The Top Line," we dive into the current state and implications of the proposed buyout. Fierce Pharma’s Fraiser Kansteiner is joined by former FTC policy director David Balto. They discuss the likelihood of the d…

1
Find out what to expect from the PDA/FDA Joint Regulatory Conference (Sponsored by Parenteral Drug Association) 13:45

3M ago13:45

13:45

In this episode of The Top Line, sponsored by the Parenteral Drug Association (PDA), we explore the upcoming PDA/FDA Joint Regulatory Conference, happening September 9-11 in Washington, D.C. Our guest, Janeen Skutnik-Wilkinson, Director of Global Quality Regulatory Surveillance and External Engagement for Moderna and Co-Chair of the 33rd annual eve…

1
A look at Big Pharma’s top-paid CEOs 10:47

3M ago10:47

10:47

Pharmaceutical CEOs often earn pay packages worth tens of millions of dollars for leading the top drugmaking companies in the industry. Every year, some new faces enter the rankings while others leave. In this week's episode of "The Top Line," Fierce Pharma’s Eric Sagonowsky and Fraiser Kansteiner discuss Fierce’s annual special report, “Big Pharma…

1
The best biopharma M&A deals 15:02

3M ago15:02

15:02

At Fierce Biotech, we love a big M&A deal, but valuation does not always equal the most exciting. In this week's episode of "The Top Line," Fierce Biotech’s Annalee Armstrong and James Waldron discuss what they think are the best and smartest acquisitions in recent years. From obesity to radiopharmaceuticals, they give you the Fierce Biotech team’s…

1
A closer look at 'friend-shoring' and the drug shortage challenge 17:54

4M ago17:54

17:54

In this week’s episode of “The Top Line,” Fierce Pharma’s Zoey Becker sits down with Bobby Sheng, the CEO of Bora Pharmaceuticals, to discuss the concept of “friend-shoring” in drug manufacturing. "Friend-shoring" involves conducting manufacturing processes in countries considered friendly or allied. Sheng discusses the criteria for deeming a count…

1
Inside this year’s ASCO: Biggest data drops, trends and the best exhibit booth 13:35

4M ago13:35

13:35

Each June, the American Society of Clinical Oncology (ASCO) hosts a conference that gathers physicians, researchers and the cancer community to share their latest research on treatments, technologies and more. The Fierce team is always on the ground at the ASCO meeting, and this year, Fierce Biotech’s Gabrielle Masson and Fierce Pharma’s Angus Liu …

1
A look at the top 10 pharma drug ad spenders 9:35

4M ago9:35

9:35

The Fierce Pharma Marketing team publishes a special report each year on the top pharmaceutical drug ad spenders. This year’s report, which includes numbers for 2023, was published on Monday. AbbVie was the standout in this edition, having spent heavily on ads for Skyrizi and Rinvoq. Overall spending on the top 10 ads also experienced a sizable inc…

1
A cell therapy reckoning 6:31

4M ago6:31

6:31

The Fierce Biotech team published a four-part series this week exploring cell therapy, a modality that has faced clinical challenges, manufacturing constraints and multiple practice-changing events. In today’s episode, Fierce’s Annalee Armstrong and Gabrielle Masson discuss the series of special reports and key insights from their interviews with m…

1
Automation, decentralization and the future of CAR-Ts: Advancements in cell & gene therapy manufacturing (Part III) 39:37

5M ago39:37

39:37

This week’s episode of “The Top Line,” is the final part of a three-part series diving into the latest advancements in cell and gene therapy manufacturing. In this episode, Fierce Pharma’s Fraiser Kansteiner is joined by Bruce Levine, Ph.D., who is the co-inventor of Kymriah and the Barbara and Edward Netter Professor in Cancer Gene Therapy at the …

1
[Sponsored] Opportunities & Challenges of Digital Pathology Adoption in CDx Development 17:00

5M ago17:00

17:00

In the fast-paced field of life sciences, digital pathology is poised to be a game-changer. In this episode, we sit down with Grace Lee and Douglas Clark of Agilent Technologies to explore the opportunities and challenges associated with companion diagnostics (CDx). Clark kicks off, shedding light on the current levels of digital pathology adoption…

1
[Sponsored] Unlocking health equity: The promise of digital health technologies 15:11

5M ago15:11

15:11

What is the transformative potential of digital health technologies in advancing health equity? Rabin Martin, a global health consulting firm, explores those possibilities in this engaging episode. The conversation highlights the excitement surrounding digital tools and advanced analytics in achieving deeper insights, consistent care delivery, work…

1
Advancements in cell & gene therapy manufacturing (Part II) 31:23

5M ago31:23

31:23

This week’s episode of “The Top Line” is the second part of a three-part series exploring the latest advancements in cell and gene therapy manufacturing. In this episode, Fierce Pharma’s Fraiser Kansteiner interviews Delara Motlagh, head of cell therapy at Catalent; Becky Butler Cap, senior vice president of biotherapies at Vitalant; and Kevin Kyle…

1
Fulfilling the promise of cell & gene therapies through manufacturing (Part I) 29:15

5M ago29:15

29:15

This week’s episode of “The Top Line,” kicks off a series diving into the latest advancements in cell and gene therapy manufacturing. In this episode, Fierce Pharma’s Fraiser Kansteiner sits down with Ori Biotech CEO Jason Foster and the Cell Therapy Manufacturing Center's CEO, Jason Bock. They delve into the current state of cell and gene therapy …

1
A closer look at 2023's top biopharma deals and what lies ahead 18:07

5M ago18:07

18:07

This week on "The Top Line," we're diving into the details of the spree of big-money biopharma deals in 2023 and examining what that means for this year. Fierce Pharma Senior Writer Kevin Dunleavy sits down with Cody Powers, a consultant who advises companies on business development and franchise growth strategy, to discuss the reasons behind the n…

1
A look at pharma revenue rankings 10:28

6M ago10:28

10:28

Fierce Pharma publishes a yearly special report highlighting the top 20 pharmas based on their revenue. The most recent edition, published this month, ranks each pharma based on their total revenues for 2023. This week on "The Top Line," Fierce Pharma Senior Editor Eric Sagonowsky and Senior Writer Kevin Dunleavy break down the numbers, highlight k…

1
Winning formulas for the best biotech and drug names 14:30

6M ago14:30

14:30

This week on “The Top Line,” we're joined by Fierce Biotech Senior Editor Annalee Armstrong and Fierce Pharma Marketing Senior Editor Ben Adams. We're diving into our recent spin on March Madness at Fierce. This time around, Fierce Biotech kicked off its inaugural Best Biotech Name tournament, while over at Fierce Pharma Marketing, we held our bian…

1
[Sponsored] What does the future of specialist distribution look like? 11:34

6M ago11:34

11:34

Jeff Beck of BioCare is in the hotseat for this edition of The Top Line. Beck is the Chief Development Officer at the company, which stands tall as a pioneer in specialty product distribution with over 40 years of experience dating back to hemophilia therapies. During the conversation, Beck provides an inside look at the rapidly evolving specialty …

1
Deep dive: Biopharma layoffs in Q1 17:47

6M ago17:47

17:47

This week on "The Top Line," we explore biopharma layoffs in the first quarter of 2024. Using data from Fierce Biotech's layoff tracker, Gabrielle Masson and Max Bayer analyze the trends of layoffs in the first quarter of 2024, comparing them to previous years. With a notable number of layoff rounds marking the start of the year, they examine the f…

1
The unrecognized threat of PAD 14:12

6M ago14:12

14:12

This week on “The Top Line,” we explore peripheral arterial disease, a serious health issue that is often overlooked and undermanaged. Join Editor-in-Chief of Fierce Life Sciences and Healthcare Ayla Ellison as she sits down with Kumar Madassery, M.D., Director of the Peripheral Vascular Intervention & CLI Program at Rush University Medical Center.…

1
The top money raisers in biotech 18:55

7M ago18:55

18:55

This week on "The Top Line," we explore our annual special report on the top money raisers in the biotech industry. Which company raised the most funding in 2023? What does the biotech financing landscape look like for this year? Fierce Biotech's Annalee Armstrong and Max Bayer answer those questions and many more in today's episode. They also disc…

1
A closer look at European biotech investment in 2024 18:28

7M ago18:28

18:28

This week on “The Top Line,” we explore the European biotech investment landscape. Fierce Biotech’s James Waldron sits down with Maina Bhaman, a Partner at Sofinnova Capital Strategy, who provides insights into how investors are approaching the European biotech sector. To learn more about the topics in this episode: 'The fundamentals are really str…

1
Inclusivity in psoriasis trials with Takeda 14:45

7M ago14:45

14:45

This week on “The Top Line,” we’re diving into the topic of diversity in clinical trials, examining both the progress made and the ongoing work needed to ensure inclusivity. In this episode, Fierce Biotech Senior Editor Annalee Armstrong engages in a conversation with Karen Correa, Ph.D., Head of Global Clinical Operations at Takeda and Executive S…

1
Fierce Medtech's Fierce 15 16:20

7M ago16:20

16:20

In this week's episode of "The Top Line," join Conor Hale, Senior Editor of Fierce Medtech, and Andrea Park, Deputy Editor of Fierce Life Sciences, as they share the highlights of this year's Fierce Medtech Fierce 15. To learn more about the topics in this episode: Fierce Medtech's Fierce 15 of 2023 See omnystudio.com/listener for privacy informati…

1
[Sponsored] A Person-Centered Approach to Achieving Long-Term Success 16:02

7M ago16:02

16:02

This week on “The Top Line,” we’re speaking with Jared Baeten, MD, Ph.D., Vice President, HIV Clinical Development, Gilead Sciences about how advancements in HIV treatment research have enabled individuals to lead longer and healthier lives by taking and staying on medication. Nevertheless, HIV persists as a significant public health challenge. To …

1
CAR-T boxed warnings: What comes next? 33:57

7M ago33:57

33:57

The FDA recently asked the six marketed CAR-T therapies to add a new boxed warning item on their labels to reflect the risk of secondary T-cell cancers. This decision follows an investigation into the new safety signal from postmarketing adverse event reports and clinical trials. In today’s episode, Fierce Pharma’s Angus Liu talks with regulatory e…

1
Breaking down Eli Lilly’s ESG formula 23:16

8M ago23:16

23:16

This week on “The Top Line,” we explore the impact of environmental, social and governance measures, commonly known as ESG, on the pharmaceutical industry. Fraiser Kansteiner of Fierce Pharma engages in a conversation with Jim Greffet, Head of ESG Strategy at Eli Lilly, to gain insights. Greffet makes a compelling business case for integrating ESG …

1
Gene editing's next act 25:44

8M ago25:44

25:44

Gene editing’s therapeutic application has transitioned from hypothetical to reality, marked by the recent approval of a CRISPR-based therapy for sickle cell and beta thalassemia. In the wake of these developments, new biotech companies are springing up spurred by advancements that redefine what conditions might soon become treatable. One contender…

1
The most anticipated drug launches of 2024 11:06

8M ago11:06

11:06

This week on “The Top Line,” we explore the most anticipated drug launches of 2024. Editor-in-Chief Ayla Ellison engages in a conversation with Fierce Pharma Marketing Senior Editor Ben Adams about the drugs likely to launch this year with the most significant sales potential by 2028. To learn more about the topics in this episode: Top 10 most anti…

1
[Sponsored] Turning information into outcomes with MedThink Communications 20:06

8M ago20:06

20:06

Should physicians consider the psychological status of patients more when developing and delivering treatment plans? What knowledge barriers are there to this? And how can these barriers be overcome? These questions lie at the heart of what John Kane has been pursuing as a healthcare communications and education expert for more than 30 years. As Ma…

Podcasts Worth a Listen

Caleb Hodgson Podcasts

Podcasts Worth a Listen

Quick Reference Guide